Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

WuXi AppTec and WuXi Biologics are reportedly looking to sell part of their operations that have struggled because of ...

The FDA's Center for Drug Evaluation and Research on Wednesday officially launched a new center of excellence to better ...

Eli Lilly’s blockbuster GLP-1 drug tirzepatide is finally back on track in the US after two years of intermittent shortages ...

Relay Therapeutics is laying off 10% of its staff, or about 30 employees, in an additional round of job cuts after a smaller ...

The UK’s publicly funded healthcare system has proposed phasing its rollout of Eli Lilly’s weight loss treatment tirzepatide ...

Novo Nordisk and Eli Lilly, whose obesity drugs are some of the most in-demand drugs in the US, have drafted plans to avoid ...

Plus, news about Caliway Pharmaceuticals, argenx, Halozyme Therapeutics, Verrica, Liquidia and Pharmosa: FDA lifts partial clinical hold on Avidity Biosciences' drug: The treatment, called delpacibart ...

Kurma Partners has closed the first part of its latest biotech-focused fund, following a pair of M&A exits for drug ...

Enara Bio has snagged $32.5 million in a Series B fundraise, backed in part by Pfizer’s venture arm, to help develop a ...

A Louisiana judge on Monday defended a new state law that keeps drugmakers from imposing certain restrictions around the ...

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, ...